Maravai LifeSciences (MRVI) vs Septerna (SEPN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Septerna (SEPN) over the past year, gaining 86.1% versus a gain of 51.1%. Septerna is the larger company by market cap ($1.84 billion vs $1.81 billion), about 1.0 times the size. Maravai LifeSciences converts more of its revenue into profit, with a net margin of -70.4% versus -106.4%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | SEPN |
|---|---|---|
| Share price | $6.98 | $38.61 |
| Market cap | $1.81B | $1.84B |
| 1-day change | -2.92% | -1.51% |
| YTD return | +114.77% | +38.49% |
| 1-year return | +86.13% | +51.06% |
| 5-year return | -83.18% | — |
| EPS (TTM) | $-0.44 | $-1.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $185.74M | $45.95M |
| Revenue growth (YoY) | -28.34% | +4174.51% |
| Net income (latest FY) | $-130.77M | $-48.88M |
| Gross margin | 18.30% | — |
| Operating margin | -115.89% | -148.63% |
| Net margin | -70.41% | -106.37% |
| 52-week high | $9.42 | $53.34 |
| 52-week low | $2.80 | $22.78 |
| Distance from 52-week high | -25.90% | -27.62% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +38.11% | +53.38% |
| Average volume | 2.72M | 383.96K |
| Shares outstanding | 149.25M | 47.55M |
| Employees | 410 | 134 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed SEPN by 35.1 percentage points over the past year.
- Maravai LifeSciences is more profitable, keeping -70.4 cents of every revenue dollar as net income versus -106.4 cents for Septerna.
- Septerna grew revenue faster in its latest fiscal year (+4174.51% vs -28.34%).
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 410 employees
About Septerna
SEPN stock →Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 134 employees
MRVI vs SEPN FAQ
Which is bigger, Maravai LifeSciences or Septerna?
Septerna (SEPN) is larger, with a market capitalization of $1.84B compared with $1.81B for Maravai LifeSciences (MRVI).
Which stock has performed better over the past year, MRVI or SEPN?
MRVI returned +86.13% over the past 12 months, compared with +51.06% for SEPN (price return, excluding dividends). Past performance does not predict future results.
Are Maravai LifeSciences and Septerna in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.